PNC-27 10 mg research-grade lyophilized peptide powder supplied in a glass vial. PNC-27 is a synthetic peptide construct typically combining a membrane-penetrating peptide sequence with a p53-derived HDM2/MDM2-binding domain and is studied in oncology-focused research models investigating selective cancer cell targeting and membrane-disruptive mechanisms.
Research Use Only: All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
High-purity research grade
Form
Lyophilized peptide powder
Content
10 mg PNC-27 per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular formula
C214H362N70O50 (representative)
Molecular weight
~4747.4 g·mol⁻¹ (representative)
Sequence / structure
(Membrane-penetrating sequence)-Linker-(p53 HDM2-binding domain sequence), e.g. RQIKIWFQNRRMKWKK-GGGSG-KKETLSPDDVQRE
In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC). For a compatible research-only solvent, see
Bacteriostatic water – 10 ml .
Research Overview
PNC-27 is a synthetic peptide construct designed for oncology research. It typically comprises a membrane-penetrating peptide segment (such as an Antennapedia-derived sequence) linked to a peptide fragment corresponding to the HDM2/MDM2-binding domain of the p53 tumor suppressor protein. In experimental in vitro and in vivo models it is used to investigate how targeting membrane-associated HDM2/MDM2 on cancer cells may influence membrane integrity, p53-related pathways and selective cytotoxic responses under controlled laboratory conditions.
Primary Research Areas
-
Targeting membrane-bound HDM2/MDM2: used in studies examining how p53-derived peptide segments interact with HDM2/MDM2 proteins localized at the plasma membrane of cancer cells and how this targeting affects signaling and membrane structure.
-
Selective cytotoxicity in cancer models: applied in experimental models exploring differential effects on transformed versus non-transformed cells, with emphasis on mechanisms that may preferentially compromise cancer cell viability in vitro.
-
Membrane disruption and cell death pathways: incorporated into research on peptide-induced membrane perturbation, pore formation, necrotic and apoptotic signaling cascades, and associated biomarker changes in cancer cell lines.
-
p53-related signaling mechanisms: used as a tool to probe interactions between the p53 pathway, HDM2/MDM2 regulation and downstream transcriptional programs in oncology-focused cell and tissue models.
-
Preclinical oncology research models: evaluated in a variety of in vitro and in vivo systems, including pancreatic, breast and hematologic cancer models, to study tumor cell responsiveness, resistance patterns and mechanistic endpoints.
